MINERVA ENDOMETRIAL ABLATION SYSTEM
Axora Medical, Inc. · Decision date Nov 5, 2026
What did the FDA decide?
The FDA recorded a 30-Day Notice decision, OK30, dated 2026-11-05 for P140013/S019, a supplement to the Minerva Endometrial Ablation System (product code MNB, obstetrics and gynecology) held by Axora Medical, Inc. The supplement reason is listed as a process change involving manufacturer, sterilizer, packager or supplier.
The recorded statement covers elimination of duplicate final QC functional testing and 30-cycle burn-in that the PMA holder performed on Minerva RF Controllers, after equivalent testing was completed at Apical Instruments. This is a manufacturing and testing change to a component of the system, not a new approval of the whole device. The source does not describe the equivalence data, the controller's role in the procedure, or any clinical implications.
FDA approval order statement
elimination of the duplicate final QC functional testing and 30-cycle burn-in performed by the PMA holder on Minerva RF Controllers following completion of equivalent testing at Apical Instruments
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Obstetrics/Gynecology
- Decision date
- Nov 5, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P140013/S019
- Regulatory pathway
- PMA supplement
- Applicant
- Axora Medical, Inc.
- Product code
- MNB
- Decision code
- OK30
- Decision date
- Nov 5, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Device, thermal ablation, endometrial.
- Applicant
- Axora Medical, Inc.
- Product code
- MNB
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P140013. Subsequent supplements may change the device or its indications.
FDA decision timeline
P140013 · Original PMA
MINERVA ENDOMETRIAL ABLATION SYSTEM
P140013/S019 received
Application receipt date recorded by FDA.
P140013/S019 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P140013. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P140013
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Axora Medical, Inc. | PMA approval | Jul 27, 2015 | FDA |
Explore the linked device profile
Other records with product code MNB
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Channel Medsystems, Inc. | PMA supplement | Nov 3, 2026 | FDA | |
Cerene Cryotherapy DeviceP180032/S024 | Channel Medsystems, Inc. | PMA supplement | Sep 15, 2026 | FDA |
Cerene Cryotherapy DeviceP180032 | Channel Medsystems, Inc. | PMA approval | Mar 28, 2019 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Axora Medical, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1 Independent Dr. Suite 2300, Jacksonville, FL, 32202
Sources and methodology
- Original FDA record: P140013/S019
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


